Cigna and Humana may still combine, expert says

The latest stories trending on MedCity News.

Editor's Pick

Top Story Cigna MA Sale to HCSC Could Still Clear Way for Humana Acquisition, Expert Says Despite Cigna and Humana ditching their pursuits to combine in December, one industry expert believes there's still a chance after Cigna announced its plan to sell its Medicare Advantage business to Health Care Service Corp. Did You See Who's Speaking at INVEST 2024? World-renowned cardiologist Dr. Henry Ting, who is currently the Senior Vice President, Chief Health & Wellness Officer, Delta Air Lines, and Adjunct Professor of Medicine, Emory University, and Professor Emeritus, Mayo Clinic. See him May 21-22 in Chicago. You can still save with the super early pricing until February 16th. Reserve Your Seat Now

Featured News

Personalized Medicine Is Revolutionizing the Role of Pharma Companies in the Healthcare Landscape The more pharma companies do to become service providers in the personalized medicine era, the more they'll succeed and the more lives they'll help to save. Coordination of Benefits: An Overlooked Pillar of Medicaid Programs Coordination of benefits is a critical pillar of the Medicaid program as it ensures the efficient use of resources, prevents overutilization, promotes equity in resource distribution, mitigates fraud and abuse, contributes to program longevity and ultimately enhances healthcare access for beneficiaries. Cohere Health Snags $50M to Speed Up Prior Authorization Prior authorization software startup Cohere Health raised $50 million on Thursday, bringing its total funding to $106 million. The need for software to streamline the prior authorization process is perhaps more evident than ever given CMS' new rule on the matter. Telehealth, Patient Reviews, and Retailization – 2024 Healthcare Digital Marketing Trends To meet evolving consumer expectations, providers must have a strong digital marketing strategy and user experience online. Here are 5 healthcare marketing trends to pay attention to in 2024. Takeda Puts Up $300M to Partner on Protagonist Drug for Rare Blood Disease Protagonist Therapeutics' rusfertide could have preliminary data next year from its Phase 3 test in polycythemia vera. If the peptide drug wins FDA approval in this rare blood disorder, the partners will share in U.S. commercialization while Takeda is responsible for the drug in the rest of the world. Look Beyond GPOs for a New World of Cost Savings There's a common belief in the healthcare industry that partnering with Group Purchasing Organizations (GPOs) […]

Resources

How To Enable a Hyperpersonal Care Experience This on-demand webinar features expert panelists from Praia Health and Providence, interviewed by AVIA to discuss the benefits of adopting a hyperpersonal care model for patients, barriers that hold health systems back, and will unpack Praia Health's technology capabilities. Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe